Zobrazeno 1 - 10
of 30
pro vyhledávání: '"Steven L McCune"'
Autor:
Enriqueta Felip, Hiroshi Tanaka, Silvia Novello, Hao Xu, Heather Wakelee, Barbara Gitlitz, Martin Reck, Wei Zou, Elizabeth Bennett, Mark McCleland, Caicun Zhou, Satoshi Oizumi, Anna Kryzhanivska, Virginia McNally, Marcus Ballinger, Meghna Das Thakur, Steven L McCune, John Hamm, Minu K Srivastava, Nasser Altorki, Rüdiger Liersch
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 10 (2023)
Background Tumor samples from the phase III IMpower010 study were used to compare two programmed death-ligand 1 (PD-L1) immunohistochemistry assays (VENTANA SP263 and Dako 22C3) for identification of PD-L1 patient subgroups (negative, positive, low,
Externí odkaz:
https://doaj.org/article/cfe63add9cfe46b48a019fc54672b05f
Autor:
Jun Li, Stefanie Zschäbitz, Daniel P Petrylak, Margitta Retz, Prabhu Bhagavatheeswaran, Marc-Oliver Grimm, Jose Perez-Gracia, Gwenaelle Gravis, Karim Fizazi, Jeffrey C Goh, Mauricio Burotto, Daniel Castellano, Fred Saad, Andrew J Armstrong, HAKIM MAHAMMEDI, Russell K Pachynski, Louis Lacombe, Diogo Assed Bastos, Steven L McCune, Juan Carlos Vázquez Limón, Edmond M Kwan, Aude Fléchon, David R Shaffer, Neha P Amin, Keziban Ünsal-Kaçmaz, Xuya Wang, Andrea Loehr
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 8 (2022)
Background CheckMate 9KD (NCT03338790) is a non-randomized, multicohort, phase 2 trial of nivolumab plus other anticancer treatments for metastatic castration-resistant prostate cancer (mCRPC). We report results from cohorts A1 and A2 of CheckMate 9K
Externí odkaz:
https://doaj.org/article/47bed5baf90f4a54860bcc0aa14ca352
Autor:
Meghan S. Karuturi, Gabrielle B. Rocque, Joseph C. Cappelleri, Joanne L. Blum, Steven L. McCune, Bijoy Telivala, Sobha Kurian, Daniel M. Anderson, Michaela Tsai, Timothy Pluard, John Migas, Yao Wang, Monica Z. Montelongo, Debu Tripathy
Publikováno v:
Cancer Research. 82:P1-18
Background: POLARIS is an ongoing, prospective, real-world, noninterventional, multicenter study in patients with HR+/HER2- ABC receiving palbociclib in the United States and Canada. This report describes PRO data from a real-world setting of patient
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d3e60ffcdf40928148874855261f0547
https://doi.org/10.1158/1538-7445.sabcs21-p1-18-25
https://doi.org/10.1158/1538-7445.sabcs21-p1-18-25
Autor:
Debu Tripathy, Zhe Zhang, Joanne L. Blum, Meghan S. Karuturi, Steven L. McCune, Bijoy Telivala, Shailendra Lakhanpal, Kamal Patel, Richard C. Frank, Kit Lu, Chetan Deshpande, Yao Wang, Yuan Liu, Aditya Bardia
Publikováno v:
Cancer Research. 82:P1-18
Background: POLARIS is a prospective, real-world study of palbociclib in patients with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC) in the United States and Canada. These ana
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1eadaff65fe3c5c11d2c5929c98b5715
https://doi.org/10.1158/1538-7445.sabcs21-p1-18-05
https://doi.org/10.1158/1538-7445.sabcs21-p1-18-05
Autor:
Félix Couture, Victoria Atkinson, Steven L. McCune, Alexander M. Menzies, Geoffrey T. Gibney, Andrew G. Hill, Georgina V. Long, Cuizhen Niu, Michael P. Brown, Blanca Homet Moreno, Stéphane Dalle, Steven J. O'Day, Caroline Robert, Matteo S. Carlino, Marcus O. Butler, Nageatte Ibrahim, Adi Diab, Jonathan Cebon
Publikováno v:
Clin Cancer Res
Purpose: Standard-dose pembrolizumab plus alternative-dose ipilimumab (1 mg/kg Q3W for 4 doses) were tolerable and had robust antitumor activity in advanced melanoma in cohort B of the phase 1 KEYNOTE-029 study. Cohort C evaluated standard-dose pembr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8f67743e03a6f91b67256825f8dfc5bc
https://doi.org/10.1158/1078-0432.ccr-21-0793
https://doi.org/10.1158/1078-0432.ccr-21-0793
Autor:
Debu Tripathy, Joanne L. Blum, Shibing Deng, Steven L. McCune, Kamal Patel, Yao Wang, Shailendra Lakhanpal, Meghan S. Karuturi, Zhe Zhang, Chetan Deshpande, Monica Z. Montelongo, Eric Gauthier, Yuan Liu, Gabrielle B. Rocque, Aditya Bardia
Publikováno v:
Cancer Research. 83:P5-02
Background: POLARIS is a prospective, real-world study of palbociclib in patients with hormone receptor–positive (HR+)/human epidermal growth factor receptor 2–negative (HER2–) advanced breast cancer (ABC) in the United States and Canada. We pr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::92eeb618c6f31e5c0de1d0d07505be70
https://doi.org/10.1158/1538-7445.sabcs22-p5-02-22
https://doi.org/10.1158/1538-7445.sabcs22-p5-02-22
Autor:
Padmanee Sharma, Michael Krainer, Fred Saad, Daniel Castellano, Jens Bedke, Mariusz Kwiatkowski, Akash Patnaik, Giuseppe Procopio, Pawel Wiechno, Samith Thomas Kochuparambil, Christian Thomas, Jose Angel Arranz Arija, Steven L. McCune, Steinbjorn Hansen, Gedske Daugaard, Neha P. Amin, Yumeng Wang, Justin M. David, Russell Kent Pachynski
Publikováno v:
Journal of Clinical Oncology. 41:22-22
22 Background: In preliminary analyses from the randomized phase 2, open-label CheckMate 650 trial, nivolumab (NIVO) 1 mg/kg (N1) plus ipilimumab (IPI) 3 mg/kg (I3) Q3W × 4 doses showed clinical activity in patients (pts) with post-chemotherapy (pos
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::11490b659e1bb3843c30cd76e4700af8
https://doi.org/10.1200/jco.2023.41.6_suppl.22
https://doi.org/10.1200/jco.2023.41.6_suppl.22
Autor:
Karim Fizazi, Margitta Retz, Daniel P Petrylak, Jeffrey C Goh, Jose Perez-Gracia, Louis Lacombe, Stefanie Zschäbitz, Mauricio Burotto, Hakim Mahammedi, Gwenaelle Gravis, Diogo Assed Bastos, Steven L McCune, Juan Carlos Vázquez Limón, Edmond M Kwan, Daniel Castellano, Aude Fléchon, Fred Saad, Marc-Oliver Grimm, David R Shaffer, Andrew J Armstrong, Prabhu Bhagavatheeswaran, Neha P Amin, Keziban Ünsal-Kaçmaz, Xuya Wang, Jun Li, Andrea Loehr, Russell K Pachynski
BackgroundCheckMate 9KD (NCT03338790) is a non-randomized, multicohort, phase 2 trial of nivolumab plus other anticancer treatments for metastatic castration-resistant prostate cancer (mCRPC). We report results from cohorts A1 and A2 of CheckMate 9KD
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::27325922e5707494b2e3d966c97e1212
https://mediatum.ub.tum.de/1686755
https://mediatum.ub.tum.de/1686755
Autor:
Michael McCleod, Alona Zer, Steven L. McCune, Marcin Kowanetz, Henry Jacob Conter, Hans-Georg Kopp, Tarek Mekhail, Niels Reinmuth, W. Lin, Ahad Sadiq, Lijia Wang, Alan Sandler, Maen A. Hussein, Federico Cappuzzo, V. Archer, Achim Rittmeyer, Davey B. Daniel, Howard Jack West, Tania Ochi Lohmann, Alessandro Morabito
Publikováno v:
The Lancet Oncology. 20:924-937
Summary Background Atezolizumab (a monoclonal antibody against PD-L1), which restores anticancer immunity, improved overall survival in patients with previously treated non-small-cell lung cancer and also showed clinical benefit when combined with ch
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9228908dbc590c8f16d533f8406c797a
https://doi.org/10.1016/s1470-2045(19)30167-6
https://doi.org/10.1016/s1470-2045(19)30167-6
Autor:
Afshin Dowlati, Oscar Juan-Vidal, Sandrine Hiret, Achim Rittmeyer, Shawgi Sukumaran, David Vicente Baz, Jorge Arturo Rios-Perez, Eric Michael Harris, Steven L. McCune, Melissa Lynne Johnson, Brandon Croft, Jesse S. McGreivy, Wayne P. Rothbaum, Javier de Castro Carpeño
Publikováno v:
Journal of Clinical Oncology. 40:TPS8600-TPS8600
TPS8600 Background: Small cell lung cancer (SCLC) is a highly aggressive neuroendocrine tumor characterized by early metastasis and a high recurrence rate with currently available treatment options. Although SCLC is generally sensitive to initial che
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::16bfa3f32e50c2308a5a5fe3ca728d80
https://doi.org/10.1200/jco.2022.40.16_suppl.tps8600
https://doi.org/10.1200/jco.2022.40.16_suppl.tps8600